New experiments under Article 51 of the Social Security Financing Act in France

31

Dec 2021

The French Ministry of Solidarity and Health constantly announces the new experiments initiated under Article 51 of the Social Security Financing Act. These experiments are focused on various topics concerning medical technologies and the organization of care. At the end of December 2021, new experiments were announced which relate to coordinated care of patients with long-term illnesses, telerehabilitation program for patients with COPD, care pathway for patients suffering from lymphedema, surgery for pterygium, and others.

Article 51 of the Social Security Financing Act allows for the financing of innovative technologies and organizational schemes in the health sector. In order to receive financing via this framework, the experiments proposed must improve healthcare access, system efficiency, the relevance of prescription, and patient pathway. With this approach, the experimentations can bypass one or more of the 63 regulations of social security financing laws, if it is on the coordination of medical pathway, relevance and quality of health, social or medico-social services, structuration of ambulatory cares and healthcare access.

At the end of December, new experiments under Article 51 of the Social Security Financing Act were announced by the Ministry of Solidarity and Health:

  • RÉMIDOM - sets up joint and coordinated care of patients with long-term illnesses by private nurses and general practitioners with total financing of the experiment estimated at €496,840 for five years of duration;
  • RR TÉLÉDOM for support of patients with chronic obstructive pulmonary disease (COPD) hospitalized for an Acute Exacerbation of COPD; support is provided through a Home Respiratory Rehabilitation program and Tele-Rehabilitation. Total financing of the experiment is estimated at €1,422,557 for four years of duration;
  • PRéCIDIVE - Prevention of recurrence of severe chronic disease by changing diet and physical activity - setting up a personalized course of recurrence prevention for anyone who is obese and has one of the chronic diseases, breast cancer, permanent diabetes after gestational diabetes, exacerbation of COPD. The total financing of the experiment is estimated at €1,034,525 for five years;
  • CLIN AVENIR - setting up outpatient chronic disease clinic run by the ClinAvenir Alliance in Toulouse with total financing of the experiment estimated at €3,532,133 for five years;
  • LYMPHORAC 51 - a coordinated care pathway for patients suffering from lymphedema with total financing of the experiment estimated at €985,384 for two years of duration;
  • EDS Pterygium - an integrated course for pterygium surgery under local anesthesia in an office with total financing of the experiment estimated at €771,045 for five years of experiment.

The full details in French can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

24

Jan 2022

In spring 2022, a new reimbursement system for remote consultations will be launched with new reimbursement codes and conditions.

Read more

19

Jan 2022

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in December 2021. More than 15 recommendations were published in relation to the registration, modification of registration conditions, renewal of registration of devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular, orthopedic, ENT devices, as well as medical aids. Except for this, CNEDiMTS published an opinion about transitional coverage (a newly established pathway for reimbursement) for a cardiovascular device.

Read more

18

Jan 2022

In December 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (endobronchial nerve ablation for chronic obstructive pulmonary disease and transanal total mesorectal excision for rectal cancer), two new Medical Technologies Guidance (ClearGuard HD antimicrobial barrier caps, and Endo-SPONGE for treating low rectal anastomotic leak), and one new Medtech Innovation Briefings (FreeO2 automatic oxygen titration). Also, one new clinical guideline was published, and five were updated.

Read more

11

Jan 2022

In December 2021, NHSX announced that the new elective recovery tech fund would support over 400 innovative digital technologies. The fund has been established to help NHS organizations accelerate the uptake of digitally supported elective care. Up to £250 million has been made available to Integrated Care Systems as a part of a £700 million Targeted Investment Fund intended to speed up elective recovery and tackle waiting lists.

Read more

04

Jan 2022

On December 15, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has announced that seventeen applications for Innovation Funding of the new forms of care were accepted.

Read more